CVS Health (CVS) Stock Forecast & Price Target

Compare

14,097 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

CVS Analyst Ratings

Strong Buy

18 Buy

1 Hold

0 Sell

Based on 19 analysts giving stock ratings to

CVS

Health

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

CVS Stock 12 Month Forecast

Average Price Target

$88.55

▲(13.41% Upside)

Based on 19 Wall Street analysts offering 12 month price targets for CVS Health in the last 3 months. The average price target is $88.55 with a high forecast of $103.00 and a low forecast of $75.00. The average price target represents a 13.41% change from the last price of $78.08.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"42":"$42","73":"$73","104":"$104","57.5":"$57.5","88.5":"$88.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":103,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$103.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":88.55,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$88.55</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":75,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$75.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[42,57.5,73,88.5,104],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Feb<br/>2025","6":"May<br/>2025","9":"Aug<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,78.15,80.06153846153846,81.97307692307693,83.88461538461539,85.79615384615386,87.70769230769231,89.61923076923077,91.53076923076924,93.4423076923077,95.35384615384615,97.26538461538462,99.17692307692307,101.08846153846154,{"y":103,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,78.15,78.95,79.75,80.55,81.35000000000001,82.15,82.95,83.75,84.55,85.35,86.15,86.95,87.75,{"y":88.55,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,78.15,77.90769230769232,77.66538461538462,77.42307692307693,77.18076923076923,76.93846153846154,76.69615384615385,76.45384615384616,76.21153846153847,75.96923076923078,75.72692307692307,75.48461538461538,75.24230769230769,{"y":75,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":53.52,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":56.66,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 48,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":43.05,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":54.85,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":63.82,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":66.02,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":68.14,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":62.4,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":68.27,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":61.96,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":73.49,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 39,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":76.25,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 53,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":78.15,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$103.00

Average Price Target$88.55

Lowest Price Target$75.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Andrew Mok CFA

Barclays

$87

Buy

11.42%

Upside

Reiterated

11/04/25

Barclays Sticks to Their Buy Rating for CVS Health (CVS)

Charles Rhyee

TD Cowen

$99→$100

Buy

28.07%

Upside

Reiterated

11/02/25

CVS Health price target raised to $100 from $99 at TD CowenCVS Health price target raised to $100 from $99 at TD Cowen

Ben Hendrix

RBC Capital

$81→$93

Buy

19.11%

Upside

Reiterated

10/31/25

CVS Health (CVS) Gets a Buy from RBC Capital

Erin Wright

Morgan Stanley

$89

Buy

13.99%

Upside

Reiterated

10/30/25

CVS Health's Turnaround Strategy: Strong Recovery and Strategic Focus for Future GrowthWe believe CVS' turnaround is still on track, which should lead to an ~in-line 3Q and maintained '25G as Part D dynamics are expected to weigh on MLR in 2H. >80% of lives in 4+ Stars sets positive tone (PY27), but '26 commentary likely deferred until I- Day on Dec. 9.

Ann Hynes

Mizuho Securities

―

Buy

―

Reiterated

10/30/25

Mizuho Securities Keeps Their Buy Rating on CVS Health (CVS)we reiterate our Outperform rating.

David S Macdonald

Truist Financial

$92→$95

Buy

21.67%

Upside

Reiterated

10/30/25

Truist Financial Reaffirms Their Buy Rating on CVS Health (CVS)

Elizabeth Anderson CFA

Evercore ISI

$85→$95

Buy

21.67%

Upside

Reiterated

10/30/25

Evercore ISI Remains a Buy on CVS Health (CVS)

Soren Coverra

TR | OpenAI - 4o

$93→$90

Buy

15.27%

Upside

Reiterated

10/30/25

AI Generated ArticleAI Generated Article

Allen Lutz

Bank of America Securities

$89

Buy

13.99%

Upside

Reiterated

10/29/25

CVS Health's Strategic Growth and Financial Resilience Underpin Buy RatingReiterate Rating: Buy | PO: 100.00 USD | Price: 82.20 USD. We reiterate our Buy rating on CVS and raise our price objective to $100 ($89 prior).

Kevin Caliendo

UBS

$79→$96

Buy

22.95%

Upside

Reiterated

10/24/25

CVS Health price target raised to $96 from $79 at UBSCVS Health price target raised to $96 from $79 at UBS

Michael Cherny

Leerink Partners

$86→$95

Buy

21.67%

Upside

Reiterated

10/17/25

Leerink Partners Sticks to Their Buy Rating for CVS Health (CVS)We reiterate our Outperform rating and raise our 12‐month price target from $86 to $95.

Lance Wilkes

Bernstein

$77

Hold

-1.38%

Downside

Reiterated

10/16/25

Bernstein Keeps Their Hold Rating on CVS Health (CVS)

Scott Fidel

Goldman Sachs

$81.93

Buy

4.93%

Upside

Initiated

10/14/25

CVS Health (CVS) Gets a Buy from Goldman Sachs

Sarah James

Cantor Fitzgerald

$78

Buy

-0.10%

Downside

Reiterated

10/10/25

Cantor Fitzgerald Reaffirms Their Buy Rating on CVS Health (CVS)Cantor Fitzgerald analyst Sarah James reiterated an Overweight rating and $78.00 price target on CVS Health (NYSE: CVS).

Stephen Baxter

Wells Fargo

$84→$103

Buy

31.92%

Upside

Reiterated

10/07/25

CVS Health price target raised to $103 from $84 at Wells FargoCVS Health price target raised to $103 from $84 at Wells Fargo

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Andrew Mok CFA

Barclays

$87

Buy

11.42%

Upside

Reiterated

11/04/25

Barclays Sticks to Their Buy Rating for CVS Health (CVS)

Charles Rhyee

TD Cowen

$99→$100

Buy

28.07%

Upside

Reiterated

11/02/25

CVS Health price target raised to $100 from $99 at TD CowenCVS Health price target raised to $100 from $99 at TD Cowen

Ben Hendrix

RBC Capital

$81→$93

Buy

19.11%

Upside

Reiterated

10/31/25

CVS Health (CVS) Gets a Buy from RBC Capital

Erin Wright

Morgan Stanley

$89

Buy

13.99%

Upside

Reiterated

10/30/25

Ann Hynes

Mizuho Securities

―

Buy

―

Reiterated

10/30/25

Mizuho Securities Keeps Their Buy Rating on CVS Health (CVS)we reiterate our Outperform rating.

David S Macdonald

Truist Financial

$92→$95

Buy

21.67%

Upside

Reiterated

10/30/25

Truist Financial Reaffirms Their Buy Rating on CVS Health (CVS)

Elizabeth Anderson CFA

Evercore ISI

$85→$95

Buy

21.67%

Upside

Reiterated

10/30/25

Evercore ISI Remains a Buy on CVS Health (CVS)

Soren Coverra

TR | OpenAI - 4o

$93→$90

Buy

15.27%

Upside

Reiterated

10/30/25

AI Generated ArticleAI Generated Article

Allen Lutz

Bank of America Securities

$89

Buy

13.99%

Upside

Reiterated

10/29/25

Kevin Caliendo

UBS

$79→$96

Buy

22.95%

Upside

Reiterated

10/24/25

CVS Health price target raised to $96 from $79 at UBSCVS Health price target raised to $96 from $79 at UBS

Michael Cherny

Leerink Partners

$86→$95

Buy

21.67%

Upside

Reiterated

10/17/25

Leerink Partners Sticks to Their Buy Rating for CVS Health (CVS)We reiterate our Outperform rating and raise our 12‐month price target from $86 to $95.

Lance Wilkes

Bernstein

$77

Hold

-1.38%

Downside

Reiterated

10/16/25

Bernstein Keeps Their Hold Rating on CVS Health (CVS)

Scott Fidel

Goldman Sachs

$81.93

Buy

4.93%

Upside

Initiated

10/14/25

CVS Health (CVS) Gets a Buy from Goldman Sachs

Sarah James

Cantor Fitzgerald

$78

Buy

-0.10%

Downside

Reiterated

10/10/25

Cantor Fitzgerald Reaffirms Their Buy Rating on CVS Health (CVS)Cantor Fitzgerald analyst Sarah James reiterated an Overweight rating and $78.00 price target on CVS Health (NYSE: CVS).

Stephen Baxter

Wells Fargo

$84→$103

Buy

31.92%

Upside

Reiterated

10/07/25

CVS Health price target raised to $103 from $84 at Wells FargoCVS Health price target raised to $103 from $84 at Wells Fargo

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering CVS Health

1 Month

xxx

Success Rate

11/18 ratings generated profit

Average Return

+0.31%

reiterated a xxx

rating 3 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 61.11% of your transactions generating a profit, with an average return of +0.31% per trade.

3 Months

xxx

Success Rate

13/21 ratings generated profit

Average Return

+5.99%

reiterated a xxx

rating 7 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 61.90% of your transactions generating a profit, with an average return of +5.99% per trade.

1 Year

Elizabeth Anderson CFAEvercore ISI

Success Rate

15/21 ratings generated profit

Average Return

+15.49%

reiterated a buy rating 7 days ago

Copying Elizabeth Anderson CFA's trades and holding each position for 1 Year would result in 71.43% of your transactions generating a profit, with an average return of +15.49% per trade.

2 Years

xxx

Success Rate

19/20 ratings generated profit

Average Return

+24.72%

reiterated a xxx

rating 8 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 95.00% of your transactions generating a profit, with an average return of +24.72% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

CVS Analyst Recommendation Trends

Rating

Jul 25

Aug 25

Sep 25

Oct 25

Nov 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, CVS has received 35 Buy Ratings, 4 Hold Ratings, and 0 Sell Ratings. CVS average Analyst price target in the past 3 months is 88.55.

Each month's total comprises the sum of three months' worth of ratings.

CVS Financial Forecast

CVS Earnings Forecast

Next quarter’s earnings estimate for CVS is $0.96 with a range of $0.89 to $1.04. The previous quarter’s EPS was $1.60. CVS beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.09% of the time in the same period. In the last calendar year CVS has Preformed in-line its overall industry.

CVS Sales Forecast

Next quarter’s sales forecast for CVS is $102.46B with a range of $99.58B to $106.13B. The previous quarter’s sales results were $102.88B. CVS beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.55% of the time in the same period. In the last calendar year CVS has Preformed in-line its overall industry.

CVS Stock Forecast FAQ

What is CVS’s average 12-month price target, according to analysts?

Based on analyst ratings, CVS Health Corp’s 12-month average price target is 88.55.

What is CVS’s upside potential, based on the analysts’ average price target?

CVS Health Corp has 13.41% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is CVS a Buy, Sell or Hold?

CVS Health Corp has a consensus rating of Strong Buy which is based on 18 buy ratings, 1 hold ratings and 0 sell ratings.

What is CVS Health Corp’s price target?

The average price target for CVS Health Corp is 88.55. This is based on 19 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $103.00 ,the lowest forecast is $75.00. The average price target represents 13.41% Increase from the current price of $78.08.

What do analysts say about CVS Health Corp?

CVS Health Corp’s analyst rating consensus is a Strong Buy. This is based on the ratings of 19 Wall Streets Analysts.

How can I buy shares of CVS?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

CVS Health (CVS) Stock Forecast & Price Target

CVS Analyst Ratings

CVS Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering CVS Health

CVS Analyst Recommendation Trends

CVS Financial Forecast

CVS Earnings Forecast

CVS Sales Forecast

CVS Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts